

U.S. FDA's PANDA Policy Could Pose Legal Problems for Biosimilars, Attorney Says

October 19, 2021

ATTORNEYS

Landmon, Chad

PRACTICE AREAS

Intellectual Property

Brenda Sandburg

Pink Sheet

Axinn partner Chad Landmon was quoted in the *Pink Sheet* article, "U.S. FDA's PANDA Policy Could Pose Legal Problems for Biosimilars, Attorney Says."

[Click here](#) to access the article. A subscription is required.